Janssen
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
AstraZeneca buys biotech Definiens
November 4, 2014Research and Development, Sales and Marketing AstraZeneca, Janssen, MedImmune, Pharmacyclics, binnig, definiens
AstraZeneca has strengthened its oncology capabilities with the acquisition of Definiens, a German company that has pioneered cancer imaging and …
BMS, Pharmacyclics and Janssen collaborate on cancer
October 14, 2014Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo
Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …
Bexsero and Sirturo clear winners at UK Prix Galien Awards
October 2, 2014Medical Communications, Research and Development, Sales and Marketing 2014, Bexsero, Janssen, Novartis, awards, prix galien, sirturo
The first TB medication to be approved in four decades and the first ever vaccine to treat invasive meningococcal disease …
J&J bets $1.75 billion on virology
October 1, 2014Research and Development, Sales and Marketing AL-8176, Alios BioPharma, J&J, JJ, Janssen, sovaldi, viral
Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral …
Janssen: why transparency is essential to the health of our industry
August 29, 2014Medical Communications, Research and Development, Sales and Marketing EFPIA, EMEA, Goldacre, Janssen, alltrials, transparency
The pharmaceutical industry is moving forward, working together to ensure patients have access to new and innovative medicines.However, more must …
Charities ‘disappointed’ in NICE and Janssen
August 15, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, prostate
The Institute of Cancer Research and Prostate Cancer UK are both urging NICE and Janssen to ‘get their act together’ …
Roche’s blood cancer drug gains EU approval
July 29, 2014Research and Development, Sales and Marketing CLL, Cancer, Gilead, Janssen, Roche
The European Commission has approved Roche’s new leukaemia drug Gazyvaro (obinutuzumab) as competition for the blood cancer market heats up. …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
NICE recommends tenth diabetes drug
June 26, 2014Sales and Marketing Janssen, NHS, diabetes, invokana, type 2
In final guidance NICE has recommended Janssen’s Invokana as a treatment to help lower blood sugar levels in people with …
Janssen abandons Simponi application
May 23, 2014Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis
Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …
Europe approves Janssen’s hep C drug Olysio
May 20, 2014Research and Development, Sales and Marketing Janssen, hepatitis C, sovaldi
Janssen-Cilag International’s Olysio has been given marketing authorisation in the European Union for the treatment of adults with hepatitis C …
NICE: no early Zytiga use
May 14, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, johnson, prostate
Janssen has criticised NICE’s decision not to recommend Zytiga on the NHS at an earlier stage in the prostate cancer …
Stelara hit by final NICE rejection
March 28, 2014Sales and Marketing Janssen, NICE, UK, arthritis, psoriatic, stelar
In final draft guidance released today NICE says it cannot recommend Janssen’s psoriatic arthritis drug Stelara. Specifically, the pricing watchdog …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
